Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease
Objective: To collect real-life data from a large cohort with Parkinson's disease (PD), with particular emphasis on drug regimens, motor complications, and quality of life…AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia
Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…Objective decrement in Parkinson’s disease – A new parameter for the BRAIN tap test
Objective: To evaluate a new parameter – Bradykinesia Index (BI) as an new objective measure within the BRAIN (BRadykinesia Akinesia INcoordination) tap test. Background: The…Safety, pharmacokinetics, and efficacy of levodopa prodrug ONO-2160/CD: A study in patients with Parkinson’s disease
Objective: The objective of this study was to evaluate the safety, pharmacokinetic profile, and efficacy of ONO-2160/carbidopa (CD) and to compare them with an immediate-release…Validation of an electronic motor diary for patients with Parkinson’s disease
Objective: To determine the reliability and compliance to electronic motor diary in patients with PD. Background: Complexity of motor complications in Parkinson's disease (PD) makes…Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human
Objective: The objective of this study was to characterize pharmacokinetic profile of levodopa prodrug ONO-2160 in animal and human. Background: Motor complications of Parkinson's disease…Construction of a levodopa-response index from wearable sensors for quantifying Parkinson’s disease motor functions: Preliminary results
Objective: The goal of the study is to investigate whether wrist worn motion sensors are feasible tools to measure motor functions in Parkinson's disease (PD).…Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I
Objective: Evaluate the efficacy of opicapone (OPC) in Parkinson's disease (PD) patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background:…Monitoring dyskinesia severity using wearable sensor data
Objective: Herein we present the results of ongoing work focused on estimating limb-specific dyskinesia in patients with PD using wearable sensor data collected in the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.